Evidence map›Paper›PMID 20947497›Full record

ArticleThe Journal of biological chemistry2010

Extended binding site on fibronectin for the functional upstream domain of protein F1 of Streptococcus pyogenes.

Lisa M Maurer, Bianca R Tomasini-Johansson, Wenjiang Ma, Douglas S Annis, Nathan L Eickstaedt, Martin G Ensenberger, Kenneth A Satyshur, Deane F Mosher

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 64 citations in OpenAlex.

  1. Fibronectin matrix assembly at a glance.Journal of cell science · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. [Science advances · 2024
    Article
  6. Article
  7. Fibronectin-targeted FUD and PEGylated FUD peptides for fibrotic diseases.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  8. Review
  9. Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. CD4Frontiers in immunology · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lisa M MaurerDepartment of Biomolecular Chemistry, University of Wisconsin, Madison, Wisconsin 53706, USA.
Bianca R Tomasini-Johansson
Wenjiang Ma
Douglas S Annis
Nathan L Eickstaedt
Martin G Ensenberger
Kenneth A Satyshur
Deane F Mosher
University of Wisconsin–Madison · US

Funding

RESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2M
STUDIES OF FIBRONECTIN AND RELATED GLYCOPROTEINSR01HL021644 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MOSHER, DEANE FREMONT · 1985 to 2010
$3.2M
NHLBI NIH HHS HL021644NHLBI NIH HHS R01 HL021644NHLBI NIH HHS T32 HL007899
6 · The paper itself

Abstract

The 49-residue functional upstream domain (FUD) of Streptococcus pyogenes F1 adhesin interacts with fibronectin (FN) in a heretofore unknown manner that prevents assembly of a FN matrix. Biotinylated FUD (b-FUD) bound to adsorbed FN or its recombinant N-terminal 70-kDa fibrin- and gelatin-binding fragment (70K). Binding was blocked by FN or 70K, but not by fibrin- or gelatin-binding subfragments of 70K. Isothermal titration calorimetry showed that FUD binds with K(d) values of 5.2 and 59 nM to soluble 70K and FN, respectively. We tested sets of FUD mutants and epitope-mapped monoclonal antibodies (mAbs) for ability to compete with b-FUD for binding to FN or to block FN assembly by cultured fibroblasts. Deletions or alanine substitutions throughout FUD caused loss of both activities. mAb 4D1 to the (2)FNI module had little effect, whereas mAb 7D5 to the (4)FNI module in the fibrin-binding region, 5C3 to the (9)FNI module in the gelatin-binding region, or L8 to the G-strand of (1)FNIII module adjacent to (9)FNI caused loss of binding of b-FUD to FN and decreased FN assembly. Conversely, FUD blocked binding of 7D5, 5C3, or L8, but not of 4D1, to FN. Circular dichroism indicated that FUD binds to 70K by β-strand addition, a possibility supported by modeling based on crystal structures of peptides bound to (2)FNI-(5)FNI of the fibrin-binding domain and (8)FNI-(9)FNI of the gelatin-binding domain. Thus, the interaction likely involves an extensive anti-parallel β-zipper in which FUD interacts with the E-strands of (2)FNI-(5)FNI and (8)FNI-(9)FNI.

Indexed as

Adhesins, BacterialAntibodies, MonoclonalBinding SitesEpitopesFibronectinsHumansProtein BindingProtein Structure, SecondaryRecombinant ProteinsStreptococcus pyogenesAdhesins, BacterialAntibodies, MonoclonalEpitopesFibronectinsRecombinant Proteins

Identifiers

PMID20947497
PMCPMC3003407
OpenAlexW1993995965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.